INNOVIVA, INC. Effective Income Tax Rate Reconciliation Fdii Amount
INNOVIVA, INC. (INVA) reported Effective Income Tax Rate Reconciliation Fdii Amount of $7.54 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount · last filed 2026-02-25
- INNOVIVA, INC. effective income tax rate reconciliation fdii amount for fiscal 2025 was $7.54M, a 35.90% decline from fiscal 2024.
- INNOVIVA, INC. effective income tax rate reconciliation fdii amount for fiscal 2024 was $11.77M, a 22.96% decline from fiscal 2023.
- INNOVIVA, INC. effective income tax rate reconciliation fdii amount for fiscal 2023 was $15.27M.
- INNOVIVA, INC. effective income tax rate reconciliation fdii amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation Fdii Amount 12 month |
|---|---|
| 2025-12-31 | $7.54M 10-K · filed 2026-02-25 |
| 2024-12-31 | $11.77M 10-K · filed 2025-02-26 |
| 2023-12-31 | $15.27M 10-K · filed 2025-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |